Future developments of nonhormonal systemic therapy for prostatic carcinoma.
Prostate cancer is the most common type of cancer in men. Despite increased public awareness and new screening methods, a significant proportion of men continue to present with metastatic disease. Most men will respond initially to hormonal intervention; however, given time, the majority will have recurrences of hormonally unresponsive tumor on which present therapies have little impact. Research continues to identify new cellular and molecular aspects of prostate cancer with implications as possible sites of therapeutic intervention.
Warner
J A
JA
Memorial Sloan-Kettering Cancer Center, New York, New York.
Heston
W D
WD
D000818:Animals; D000970:Antineoplastic Agents / Q000627:therapeutic use; D006133:Growth Substances / Q000378:metabolism / Q000502:physiology; D006801:Humans; D008297:Male; D009857:Oncogenes / Q000502:physiology; D011471:Prostatic Neoplasms / Q000188:drug therapy* / Q000378:metabolism / Q000503:physiopathology
D000970:Antineoplastic Agents; D006133:Growth Substances